baber/WOPTO huggingface dataset:
Patent NZ-563999-A (NZ)
Title: Suspended ceiling system grid with slots to access conductive strips
Inventor: FRECSKA SANDOR
IPC: E04B2/00
Filed: 2006-05-11
Abstract: Disclosed is a suspended ceiling system with accessible electrical conductivity. The system comprises of a plurality of grid elements (10) forming a grid network arranged in a substantially horizontal plane. A grid element extends longitudinally and includes first and second access slots (22, 24), the slots being longitudinally and vertically offset from one another. The system further comprises first and second conductive strips (40) having opposing polarity. The strips are partially embedded in the grid element such that at least a portion of each of the first and second conductive strips is exposed. A tap is attached to the grid element, the tap providing conductive strip engaging means. The combination of the conductive strips and the tap provides electricity to the ceiling environment which is accessible from above, below and within the plane of the grid network.
Patent NZ-565039-A (NZ)
Title: Compositions and methods for less immunogenic protein-lipid complexes
Inventor: BALU-IYER SATHY V
IPC: A61K9/127
Filed: 2006-06-29
Abstract: Disclosed is a pharmaceutical composition comprising liposomes comprising: a) phosphatidyl ethanolamine (PE) derivatized with polyethylene glycol (PEG), b) an amphipathic lipid selected from the group consisting of phosphatidyl choline, phosphatidylglycerol, and combinations thereof, and optionally, PE, c) a negative charged lipid selected from the group consisting of phosphatidylserine (PS), phosphatidic acid (PA) and combinations thereof; and d) Factor VIII, wherein the immunogenicity of Factor VIII is reduced over the immunogenicity of free Factor VIII.
Patent NZ-574245-A (NZ)
Title: Method for identifying genes that are homologous to known pesticidal genes, particularly Bacillus thuringiensis (Bt) Cry genes
Inventor: ABAD ANDRE R
IPC: C12Q1/68
Filed: 2007-07-20
Abstract: Disclosed are methods for identifying novel pesticidal genes that share regions of homology with known genes from target groups of genes of interest, particularly Bacillus thuringiensis Cry genes. The methods comprise systematically designing oligonucleotide primers that are specific for regions of homology within the nucleotide sequences of a target group of known genes and performing successive rounds of PCR amplification of nucleic acid material from an organism of interest. The PCR steps are intended to identify and amplify nucleic acids comprising both known and novel genes. Nucleic acid molecules comprising known genes are detected and eliminated from further consideration by dot blot analysis using oligonucleotide probes specific for the known genes in the target group. Potentially novel genes are subjected to further sequence analysis to confirm novelty and assayed for biological activity.
Patent NZ-575672-A (NZ)
Title: 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors
Inventor: DUGGAN HEATHER MARY ELLEN
IPC: C07D471/04
Filed: 2007-08-21
Abstract: The disclosure relates to 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivative compounds of formula (I), wherein the variables are as defined in the specification, and pharmaceutically acceptable salts thereof; processes for the manufacture of compounds of formula (I), and the use of compounds of formula (I) as a medicament and in the treatment of cancer.
Patent NZ-576751-A (NZ)
Title: Anti-angiogenic compounds
Inventor: BRADSHAW CURT
IPC: A61K38/18
Filed: 2007-11-12
Abstract: Disclosed is an anti-angiogenic targeting agent comprising a peptide comprising the sequence R1-Q1 (ACK)2 Y3 Q4 P5 L6 D7 E8 (ACK) 9 D10 K11 T12 L13 Y14 D15 Q16 F17 M18 L19 Q20 Q21 G22-R2 wherein the substituents are as defined in the specification. Also disclosed is the anti-angiogenic targeting agent attached to a linker or branched linker.
Patent NZ-578566-A (NZ)
Title: Interchangeable adapter for replaceable explosive fuel cells for fastener driving tools
Inventor: GIBSON ERIC S
IPC: B25C7/00
Filed: 2008-01-17
Abstract: Disclosed is a fuel cell assembly for a fastener driving tool. The assembly comprises an in-can or an on-can fuel cell having a closure formation and an adapter including a ring portion configured for engagement upon the fuel cell closure formation and including a top edge, a bottom edge and a sidewall in between. The sidewall has an inner sidewall and an outer sidewall, the inner sidewall defining at least one track extending from the top edge to the bottom edge. The outer sidewall has a convex gripping formation complementary to the closure formation. An in-can cap or an on-can fuel metering valve is constructed and arranged for being removably secured to the adapter and including a leg portion having a foot constructed and arranged for being received in an undercut portion. The adapter further includes at least one notch, each notch defined in the inner sidewall adjacent to a corresponding one of the tracks and configured for receiving a corresponding foot for securing the adapter in a shipping position.
Patent NZ-579819-A (NZ)
Title: Recess former for concrete panel
Inventor: MACKAY SIM ROD
IPC: E02D35/00
Filed: 2009-09-22
Abstract: A recess former 70 for use with anchors 80 which are to be cast into a concrete slab or other concrete element within formwork, includes magnetic implants 76. Magnetic attraction between the magnetic implants 76 and the ferromagnetic anchor 80 prevents dislodgement of the anchor 80 from the recess former 70 and maintains mechanical engagement between the anchor 80 and the body halves 71A, 71B of the recess former so that cement does not enter the hollow of the former during casting. The former is adapter to lie alongside the formwork without actually being connected to the formwork. (61) Addition to 573621
Patent NZ-589451-A (NZ)
Title: Antibodies against fcrn and use thereof
Inventor: TENHOOR CHRISTOPHER
IPC: A61P37/00
Filed: 2009-04-24
Abstract: Disclosed is an isolated antibody comprising a heavy chain (HC) immunoglobulin variable domain sequence and a light chain (LC) immunoglobulin variable domain sequence, wherein the heavy chain and light chain immunoglobulin variable domain sequences form an antigen binding site that binds to human FcRn and wherein the HC comprises: a HC CDR1 comprising an amino acid sequence at least 85% identical to EYAMG (SEQ ID NO:144) or VYAMG (SEQ ID NO:156), a HC CDR2 comprising an amino acid sequence at least 85% identical to SIGSSGGQTKYADSVKG (SEQ ID NO:145), or SIGSSGGPTKYADSVKG (SEQ ID NO:157), and a HC CDR3 comprising an amino acid sequence at least 85% identical to LSTGELY (SEQ ID NO:146), LSIRELV (SEQ ID NO:158), LSIVDSY (SEQ ID NO:164), LSLGDSY (SEQ ID NO:170), or LAIGDSY (SEQ ID NO:176); and the LC comprises: a LC CDR1 comprising an amino acid sequence at least 85% identical to TGTGSDVGSYNLVS (SEQ ID NO:141), a LC CDR2 comprising an amino acid sequence at least 85% identical to GDSQRPS (SEQ ID NO:142), and a LC CDR3 comprising an amino acid sequence at least 85% identical to CSYAGSGIYV (SEQ ID NO:143).
Patent NZ-590498-A (NZ)
Title: Impeller for blower with vanes sandwiched between shrouds with opposite corners of vanes not in contact with shrouds
Inventor: KENYON BARTON JOHN
IPC: A61M1/00
Filed: 2006-10-27
Abstract: An impeller comprising: a top shroud; a bottom shroud, a plurality of vanes sandwiched between the top shroud and the bottom shroud, each said vane including a top edge at a radially inner portion of the vane in contact with the top shroud and a bottom edge at a radially outer portion of the vane in contact with the bottom shroud, such that a radially inner portion of the vane at the bottom edge of each vane is not in contact with or adjacent the bottom shroud and a radially outer portion of the vane at the top edge of each vane is not in contact with or adjacent the top shroud.
Patent NZ-592392-A (NZ)
Title: PHENANTHROINDOLIZIDINE COMPOUND AND NFkB INHIBITOR CONTAINING SAME AS ACTIVE INGREDIENT
Inventor: IKEDA TAKASHI
IPC: A61P37/02
Filed: 2009-10-23
Abstract: Disclosed herein are phenanthiroindolizidine derivatives of formula (I), wherein the substituents are as defined within the specification, processes for its preparation, compositions comprising said compounds and uses thereof. Said compounds are useful as Nuclear Factor-?B (NF?B) inhibitors and is therefore useful in the treatment of diseases associated with accelerated NF?B activity, such as cancer.
Patent NZ-593884-A (NZ)
Title: Duckbill flip cap fitment for a collapsible container
Inventor: JOHNSON JAMES W
IPC: B65D1/02
Filed: 2010-01-07
Abstract: 593884 Disclosed is a fitment for use on a collapsible bag for dispensing liquids or semi-solids from the bag. The fitment comprises a spout (50) having a generally cylindrical body attached to the collapsible bag, a slidably removable tubular probe assembly (10) and a cap (30), having a flexible cap duckbill (20) positioned within an opening (32) in the cap, attached to the spout. The cap further includes an outer collar, an inner collar and a hollow cylinder section fixedly attached to the inner collar at one end. The tubular probe assembly allows for the flow of fluid when engaged with a probe assembly (10) and reversibly seals upon removal of the tubular probe assembly. This advantageously prevents the backflow of fluid from the collapsible bag when the probe assembly is not attached.
Patent NZ-595119-A (NZ)
Title: Use of butanol and ethanol in fuels for spark ignition engines
Inventor: KUBERKA MELANIE
IPC: C10L1/00
Filed: 2009-02-05
Abstract: Disclosed is a method of manufacturing a fuel for spark-ignition engines, the fuel comprising 15-50 per cent by volume of base fuel, 15-65 per cent by volume of ethanol and 15 to 50 per cent C4 alcohol (butanol / butyl alcohol), which method comprises mixing: (i) a mixture I, comprising 15-30 per cent by volume of a base fuel and 70-85 per cent by volume of ethanol; with (ii) a mixture II, comprising 30-50 per cent by volume of base fuel and 50 to 70 per cent by volume of C4 alcohol.
Patent NZ-596369-A (NZ)
Title: Method, system, and apparatus for searching an electronic document collection
Inventor: RESNICK JASON DAVID
IPC: G06F17/30
Filed: 2009-05-07
Abstract: 596369 Disclosed is a computer-implemented method for searching on an electronic document collection. The method includes compiling and indexing, by a processor, a collection of intellectual property documents, each of the documents in the collection having multiple sections. The method also includes identifying, by a processor, each of the sections of each document in the collection. A processor also organises a search profile for the document collection, wherein the search profile includes a selection of at least one of the identified sections of each document in the compiled collection. Within the organised search profile, a processor assigns a weight to each of the identified and selected sections. At query time, a query is submitted to the intellectual property document collection. Submitting a query includes selecting at least one search profile, and comparing query data with data in each of the document sections of the selected profile in the collection with an assigned weight. The processor also modifies one or more assigned weights by adding or subtracting one or more secondary weights from each assigned weight based on the quantity of the query matching with one or more sections corresponding to the one or more assigned weights. The method further includes generating by a processor a compilation of relevant documents generated from the query submission, including a match of the submitted query to data in at least one identified profile section having an assigned weight.
Patent NZ-599323-A (NZ)
Title: Affinity ligands and methods for protein purification
Inventor: HEARN MILTON TW
IPC: B01D15/08
Filed: 2010-10-15
Abstract: ABSTRACT: 599323 The disclosure relates generally to affinity ligands and chemical affinity ligand-matrix conjugates for use as chromatographic adsorbents and methods which utilise the adsorbents in the purification of proteins by affinity chromatography. These affinity ligand-matrix conjugates comprise ligands of general formula (I): wherein m represents an integer from 0-2, n represents an integer from 0-6, p represents an integer from 0-4, R1 represents H or C1-3 alkyl, R2 is an optional substituent as defined in the specification, and X is the position at which the ligand is immobilized, optionally via a linker.
Patent NZ-601866-A (NZ)
Title: Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders
Inventor: LITTLE THOMAS
IPC: A01N29/02
Filed: 2008-06-30
Abstract: 601866 Disclosed is an ethyne substituted phenyl compound of formula (A) where the substituents are as disclosed in the specification. Examples of a compounds of formula (A) are: -(3-((2,6-imethylphenyl)ethynyl)phenyl)propan-1-amine; 4-(3-(3-aminopropyl)phenyl)but-3-yn-1-ol; 1-(3-(3-aminopropyl)phenyl)-3-ethylpent-1-yn-3-ol; 1-((3-(3-aminopropyl)phenyl)ethynyl)-2,2,6,6-tetramethylcyclohexanol; 4-((3-(3-aminopropyl)phenyl)ethynyl)tetrahydro-2H-pyran-4-ol; 3-(3-(pyridin-4-ylethynyl)phenyl)propan-1-amine; 1-(3-(2-aminoethoxy)phenyl)-3-isopropyl-4-methylpent-1-yn-3-ol; and 1-((3-(1-aminopropan-2-yloxy)phenyl)ethynyl)cycloheptanol. Also disclosed are pharmaceutical compositions comprising a compound of formula (A) and the use of a compound of formula (A) in the manufacture of a medicament. The medicament is useful for modulating chromophore flux in a retinoid cycle; for the treatment of an ophthalmic disease or disorder in a subject and for the treatment of age-related macular degeneration or Stargardt's macular dystrophy.
Patent NZ-602766-A (NZ)
Title: Air blown asphalt including polyphosphoric acid
Inventor: MARTIN JEAN-VALERY
IPC: C10C3/04
Filed: 2009-04-07
Abstract: Disclosed is air blown asphalt produced by a process comprising the steps of: (a) providing an asphalt composition; (b) treating the asphalt by air blowing at a temperature from 350ºF to 550ºF for a period of time from 60 minutes to 700 minutes; (c) following the air blowing treatment, adding polyphosphoric acid having an equivalent value from 105% to 118% to the asphalt to achieve a concentration from 0.1% by weight to 3% by weight while stirring.
Patent NZ-613865-A (NZ)
Title: Rna antagonist compounds for the modulation of beta-catenin
Inventor: WORM JESPER
IPC: C12N15/11
Filed: 2008-04-30
Abstract: Disclosed is an oligomer of between 16 - 24 nucleobases in length, wherein said oligomer comprises a gapmer nucleobase sequence of SEQ ID NO: 103 (gtgttctacaccatta), and wherein the oligomer is capable of inhibiting the expression of beta-catenin gene or mRNA in a cell which is expressing betacatenin gene or mRNA.
Patent NZ-620948-A (NZ)
Title: Noribogaine salt ansolvates
Inventor: GLESS RICHARD D
IPC: C07D223/14
Filed: 2012-09-14
Abstract: Disclosed are noribogaine salt ansolvates and phosphate salt polymorphs prepared by slurrying methanol solvated forms of the salt in ethanol/water. The disclosed noribogaine salt ansolvates are more stable and less dense providing the advantage of more compact and smaller tablets than solvated polymorphs for tableting while using the same amount of a noribogaine salt. The noribogaine salt ansolvates are useful for preparing pharmaceutical compositions for alleviating nociceptive pain in a patent.
Patent NZ-623871-A (NZ)
Title: Implantable medical devices with increased immune tolerance, and methods for making and implanting
Inventor: BAR-OR DAVID
IPC: C07D241/08
Filed: 2012-10-10
Abstract: Disclosed herein is a method for the preparation of implantable medical devices and implants comprising the contacting of one or more surfaces of an implantable medical device with one or more diketopiperazines (DKPs) of the formula I.
Patent NZ-627709-A (NZ)
Title: Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
Inventor: CHA MI YOUNG
IPC: A61K31/381
Filed: 2011-06-20
Abstract: Disclosed are furo[3,2-d]pyrimidine derivatives of formula (I) or a pharmaceutically acceptable salt thereof, wherein, W is O; X is O, NH, S, SO or SO2; Y is hydrogen, halogen, alkyl or alkoxy; A and B are each independently hydrogen atom, halogen atom, or di(alkyl)aminomethyl; Z is optionally substituted aryl or optionally substituted heteroaryl; optionally, the alkyl is partially unsaturated or has a cycloalkyl moiety. Representative compounds include N-(3-((2-((4-(4-methylpiperazin-1-yl)phenyl)amino)furo[3,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide, N-(3-((2-((4-(4-isopropylpiperazin-1-yl)phenyl)amino)furo[3,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide, N-(3-((2-((4-morpholinophenyl)amino)furo[3,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide, N-(3-((2-((4-((dimethylamino)methyl)phenyl)amino)furo[3,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide, N-(3-((2-((4-((4-(dimethylamino)piperidin-1-yl)methyl)phenyl)amino)furo[3,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide, N-(3-((2-((3-fluoro-4-(1-methylpiperazin-4-l)phenyl)amino)furo[3,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide, N-(3-((2-((4-(2-dimethylamino)ethyl)amino)-3-fluorophenyl)amino)furo[3,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide, N-(3-((2-((3-fluoro-4-((1-methylpiperidin-4-yl)amino)phenyl)amino)furo[3,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide, N-(3-(2-(3-methoxy-4-(4-methyl-piperazin-1-yl)-phenylamino)-furo[3,2-d]pyrimidin-4-yloxy)-phenyl)-acrylamide and N-(3-((2-((4-sulfamoylphenyl)amino)furo[3,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide. Further disclosed is a pharmaceutical composition for preventing or treating cancers, tumours, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases which comprises the compound of formula (I) as defined above or its pharmaceutically acceptable salt as an active ingredient.
Patent NZ-701416-A (NZ)
Title: Securing of sheet material which is in the form of a liner, a cover or a curtain
Inventor: PIERRE CORVISIER
IPC: F16B5/06
Filed: 2014-10-28
Abstract: A system for hanging a liner (56) in a shipping container, the system having clips (10.2) that may be slidingly adjusted along an attachment zone (60) of the liner (56), to align with the position and spacing of lashing points (64) on the shipping container. A cord (62) is passed alternatingly through each set of clips (10.2) and lashing points (64) and raises the liner (56) into place when tightened. The system overcomes the problem of attaching a liner (56) to different shipping containers which may have varyingly spaced lashing points (64). The system comprises two sets of clips (10.2) each of which sets is located where an elongate top panel of the liner (56) is joined to an elongate side panel of the liner (56). Each clip (10.2) has an elongate hollow portion (12) having a longitudinal slit (14) along the length thereof. The liner (56) has a thickened edge portion (60), this being the attachment zone which, in use, is in the elongate hollow portions (12) of the clips. The liner (56) emerges from each clip (10.2) through the longitudinal slit (14) whilst the attachment zone (60) is trapped in the elongate hollow portions (12). The shipping container has lashing points (64). Cords (62) are passed through the passageways (40) of each set of clips (10.2) and through hooks (42) on the lashing points (64). The clips (10.2) and lashing points (64) alternate along the length of each cord (62). The clips (10.2) can slide along the attachment zone (60) to adjust their positioning such that, in use, each clip (10.2) is positioned substantially under one of the lashing points (64).
Patent NZ-710157-A (NZ)
Title: Use of guanethidine for treating hypertension by local vascular delivery
Inventor: SEWARD KIRK PATRICK
IPC: A61K31/155
Filed: 2010-04-22
Abstract: Disclosed is the use of a botulinum neurotoxin or fragment thereof in the preparation of a medicament for treating hypertension in a human patient by lowering systemic blood pressure in the human patient, wherein the botulinum neurotoxin or fragment thereof is to be administered into a tissue surrounding a renal blood vessel and surrounding renal nerves by injection into the tissue.
Patent NZ-711566-A (NZ)
Title: Formulations with reduced oxidation
Inventor: ALAVATTAM SREEDHARA
IPC: A61K31/405
Filed: 2014-03-13
Abstract: The invention provides formulations comprising a protein in combination with a compound that prevents oxidation of the protein. The invention also provides methods for making such formulations and methods of using such formulations. The invention further provides methods of screening for compounds that prevent oxidation of a protein in a protein composition and methods of preventing oxidation of a protein in a formulation. Compounds which prevent said oxidation of protein include 5-hydroxy-L-tryptophan, 5-hydroxy-indole, 7-hydroxy-indole and serotonin (5-hydroxy-tryptamine).
Patent NZ-712058-A (NZ)
Title: Gla domains as targeting agents
Inventor: BAUZON MAXINE
IPC: C07K14/745
Filed: 2014-03-13
Abstract: The disclosure relates to the recombinant Gla domain proteins and their use targeting phosphatidylserine (PtdS) moieties on the surface of cells, particularly those expressing elevated levels of PtdS, such as cells undergoing apoptosis. These proteins can be linked to both diagnostic and therapeutic payloads, thereby permitting identification and treatment of cells expression elevated PtdS.
Patent NZ-718076-A (NZ)
Title: Inhibitors of the fibroblast growth factor receptor
Inventor: BIFULCO NEIL
IPC: C07D409/12
Filed: 2014-10-23
Abstract: Described herein are inhibitors of FGFR-4 of the formulae I and II, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
Patent NZ-731635-A (NZ)
Title: Headgear assembly for a respiratory mask assembly
Inventor: GUNEY MEMDUH
IPC: A61M16/06
Filed: 2003-09-05
Abstract: A headgear assembly to stabilize and position a respiratory mask assembly on a patient’s head to maintain the respiratory mask assembly in a desired adjusted position on a patient’s face during use, the headgear assembly comprising: a pair of upper side strap portions, each of the pair of upper side strap portions configured to extend across a corresponding lateral side of the patient’s head and superior to the patient’s corresponding ear and eye in use; a pair of lower side strap portions, each of the pair of lower side strap portions configured to extend across a corresponding lateral side of the patient’s head and inferior to the patient’s corresponding ear in use; an upper strap portion connecting the pair of upper side strap portions and configured to prevent movement of the headgear assembly in an inferior direction on the patient’s head in use; a rear lower strap portion connecting the pair of lower side strap portions; a rear cross-bar strap portion positioned inferior to the upper strap portion and superior to the rear lower strap portion in use; a pair of upper intermediate strap portions, each of the pair of upper intermediate strap portions connecting a corresponding one of the pair of upper side strap portions to the rear cross-bar strap portion; and a pair of lower intermediate strap portions, each of the pair of lower intermediate strap portions connecting the rear cross-bar strap to the rear lower strap portion, wherein the upper strap portion, the pair of upper intermediate strap portions, and the rear cross-bar strap portion define an upper opening, wherein the rear lower strap portion, the pair of lower intermediate strap portions, and the rear cross-bar strap portion define a lower opening, and wherein the upper opening and the rear lower opening are dimensioned such that the upper opening is configured to accommodate a larger portion of the patient’s head in use than the rear lower opening.